Touchstone Strategic Trust has filed a summary prospectus for its Touchstone Value Fund, providing essential information about fees and expenses associated with the fund. This filing, made on October 27, 2026, is significant as it enhances transparency for investors and reflects the company's commitment to clear communication in the investment landscape.
Touchstone Strategic Trust, incorporated in Massachusetts, operates as an investment entity. The company is known for its various investment funds, including the Touchstone Value Fund, which aims to deliver long-term capital growth. The recent filing is part of a series of submissions, including multiple 497K forms filed on the same day, indicating a proactive approach to updating investors.
The filing states, "Before you invest, you may want to review the Fund’s prospectus, which contains information about the Fund and its risks." This highlights the importance of understanding the associated costs and risks before making investment decisions. The prospectus outlines various classes of shares available, including Class A, Class C, Institutional Class, Class Y, and Class R6, each with different fee structures.
The Touchstone Value Fund's total annual operating expenses range from 1.10% for Class A shares to 2.68% for Class C shares. The filing also mentions the potential for sales charge discounts, emphasizing the company's strategy to attract a broad range of investors. The fund's management fees are set at 0.58%, with additional distribution and shareholder service fees varying by class.
This update may affect current and potential investors, as it provides a clearer picture of what to expect in terms of costs when investing in the Touchstone Value Fund. The detailed disclosure of fees and expenses aligns with regulatory expectations and investor demands for transparency in the investment industry.
Looking ahead, Touchstone Strategic Trust may continue to file additional updates and prospectuses to keep investors informed about changes in fund management and performance. The filing does not specify what happens next, but ongoing communication will be crucial for maintaining investor confidence.
Read Next
uniQure's ifezuntirgene inilparvovec BLA Accepted by FDA
Flowco Holdings Inc. files 8-K detailing financial updates
Diageo reports total voting rights for October 2026
Shell plc executive sells 33,000 shares in company
TAT Technologies Reports Strong Q3 2026 Financial Results
Eton Pharmaceuticals Launches ET-900 Program for Spasms








